Efficacy of dual-specific Bcr-Abl and Src-family kinase inhibitors in cells sensitive and resistant to imatinib mesylate.

MLA

Tipping, A. J., et al. “Efficacy of Dual-Specific Bcr-Abl and Src-Family Kinase Inhibitors in Cells Sensitive and Resistant to Imatinib Mesylate.” Leukemia, vol. 18, no. 8, Aug. 2004, pp. 1352–56. EBSCOhost, https://doi.org/10.1038/sj.leu.2403416.

APA

Tipping, A. J., Baluch, S., Barnes, D. J., Veach, D. R., Clarkson, B. M., Bornmann, W. G., Mahon, F. X., Goldman, J. M., & Melo, J. V. (2004). Efficacy of dual-specific Bcr-Abl and Src-family kinase inhibitors in cells sensitive and resistant to imatinib mesylate. Leukemia, 18(8), 1352–1356. https://doi.org/10.1038/sj.leu.2403416

Chicago

Tipping, A J, S Baluch, D J Barnes, D R Veach, B M Clarkson, W G Bornmann, F X Mahon, J M Goldman, and J V Melo. 2004. “Efficacy of Dual-Specific Bcr-Abl and Src-Family Kinase Inhibitors in Cells Sensitive and Resistant to Imatinib Mesylate.” Leukemia 18 (8): 1352–56. doi:10.1038/sj.leu.2403416.